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Abstract
. Postpartum haemorrhage (PPH) is a leading cause of maternalBackground
death. Tranexamic acid (TXA) has the potential to reduce bleeding and a large
randomized placebo controlled trial of its effect in women with PPH (The
WOMAN trial) is underway. TXA might also affect coagulation factors and
platelets. . To examine the effect of TXA on thrombin generation,Objectives
platelet function, fibrinogen, D-dimer and coagulation factors in women with
PPH. . We will conduct a sub-study within the WOMAN trial. WomenMethods
with clinically diagnosed primary PPH after vaginal or caesarean delivery are
eligible for inclusion. Blood samples will be collected at baseline and 30
minutes after the first dose of study treatment. Using platelet poor plasma we
will measure thrombin generation, fibrinogen, D-dimer, factor V and VIII, and
Von Willebrand factor. Platelet function will be evaluated in whole blood using
Multiplate® tests. . The primary outcome is the effect of TXA onOutcomes
thrombin generation. Secondary outcomes include the effect of TXA on platelet
function, fibrinogen, D-dimer and coagulation factors.
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Abbreviations
ADPtest: Test of Adenosine Di Phosphate; AUC: Area Under 
Curve; CI: Confidence Interval; CBC: Complete Blood Count; 
DMC: Data Monitoring Committee; ETP: Endogenous Thrombin 
Potential; FV: Coagulation Factor V; FVIII: Coagulation Factor 
VIII; ICH GCP: International Conference on Harmonisation of 
Good Clinical Practice; LT: Lag Time; LSHTM: London School 
of Hygeine and Tropical Medicine; PH: Peak Height; MPV: Mean 
Platelet Volume; PPH: postpartum haemorrhage; SAP: Statisti-
cal Analysis Plan; SOP: Standard Operating Procedure; TtP: time 
to peak; TGA: Thrombin Generation Assay; TXA: Tranexamic 
Acid; TRAPtest: Test of Thrombin Receptor of Thrombocyte; TCC: 
Trial Coordinating Centre; TSC: Trial Steering Committee; vWF: 
Coagulation Factor Von Willebrand.
Background
Tranexamic acid (TXA) reduces bleeding by inhibiting the 
enzymatic degradation of fibrin blood clots by the serine protease 
plasmin. During fibrinolysis, plasminogen binds to fibrin via lys-
ing binding sites, where it is converted to the active fibrinolytic 
enzyme plasmin by tissue plasminogen activator. TXA is a molec-
ular analogue of lysine that inhibits fibrinolysis by reducing the 
binding of plasminogen to fibrin. TXA reduces surgical bleeding 
and in 2010, the CRASH-2 trial showed that TXA reduces death 
due to bleeding in trauma patients (Roberts & Prieto-Merino, 
2014). TXA also has the potential to reduce death due to bleeding 
in PPH. The WOMAN trial is investigating the effect of TXA on 
mortality and morbidity in women with PPH.
In addition to its role in fibrinolysis, plasmin has various effects 
on coagulation factors. Coagulation factors V (FV) and VIII 
(FVIII) are first activated and then inactivated by plasmin. The 
initial activation of these factors may generate enough thrombin to 
have a pro-coagulant effect. Plasmin might also promote thrombin 
generation by inactivating tissue factor pathway inhibitor, a major 
inhibitor of tissue factor-mediated thrombin generation (Godier 
et al., 2012). Ogiwara et al. (2010) showed that thrombin genera-
tion is increased in the presence of plasmin. If plasmin increases 
thrombin production, TXA, by inhibiting plasmin production, 
should reduce thrombin generation.
Although TXA reduces bleeding by inhibiting fibrinolysis, it may 
reduce bleeding through other mechanisms. For example, TXA 
may improve platelet function (Boylan et al., 1996). The expo-
sure of platelets with plasmin induces platelet activation (Ervin & 
Peerschke, 2001). Plasmin activates platelets via different mech-
anisms, such as stimulating the arachidonic acid cascade, and 
inducing platelet degranulation and complement activation (Godier 
et al., 2012). The main effect of TXA on platelet function may be 
due to the inhibition of plasmin, and consequently the decrease of 
plasmin’s multifactorial induction on platelets.
TXA improved platelet function in cardiac surgery patients, with 
impaired platelet function caused by preoperative exposure of 
antiplatelet therapy, such as clopidogrel (Shi et al., 2013). Another 
study in cardiac surgery patients (Weber et al., 2011) noticed that 
administration of TXA significantly improved platelet function 
by attenuating platelet aggregation defects created by antiplatelet 
treatment.
In patients with chronic renal failure, administration of TXA cor-
rected platelet aggregation defects (Mezzano et al., 1999), and 
as result improved platelet function. Also, Sabovic et al. (2005) 
reported that platelet dysfunction in haemodialysis patients was 
effectively corrected with long term administration of TXA at a low 
dose.
Methods and study design
Objective
The study will assess the effect of TXA on thrombin generation, 
coagulation factors and platelet function in women with PPH, in 
particular, the effects of TXA on thrombin generation, factor V 
(FV), factor VIII (FVIII), Von Willebrand factor (vWF), fibrinogen, 
D-dimers and platelet function. We hypothesize that by inhibit-
ing plasmin, TXA will decrease thrombin generation, and modify 
platelet activity, FV, FVIII and vWF levels, in patients with PPH.
Trial design
The WOMAN-ETAPlaT is a sub-study of the World Maternal 
Antifibrinolytic Trial, an international randomized, double blinded, 
placebo-controlled trial. As a sub-study, there are no changes to the 
study design of the WOMAN trial, but for the specific design of the 
sub-study there are some additional examinations and laboratory 
tests.
Participants and eligibility criteria. Inclusion criteria: Partici-
pants in the study are women ≥18 years old with a clinical diagnosis 
of postpartum haemorrhage (PPH) after vaginal or caesarean birth. 
All available treatment for PPH should be given, and inclusion in 
the study should be considered as soon as possible after patient 
consent has been obtained. Clinically diagnosed PPH can be estab-
lished with one of the following conditions: amount of blood lost 
following vaginal birth is >500mL or >1,000mL after caesarean 
birth; or enough blood loss has compromised the patient’s hemo-
dynamic status. Exclusion criteria: Patients diagnosed with PPH, 
for whom the physician believes that there is a secure indication or 
contraindication for use of TXA, should not be randomised.
Study setting. For the conduct of this sub-study, a single site has 
been chosen, the Obstetric Gynaecology University Hospital ”Koço 
Gliozheni” in Tirana, Albania. This is justified because PPH is the 
main cause of maternal mortality in Albania. The hospital offers ter-
tiary health care and is a national referral hospital for other obstetric 
gynaecology hospitals in the country.
Interventions. Patients with clinically diagnosed PPH and fulfill-
ing the eligibility of the WOMAN trial will be randomized into the 
study after the administration of the standard treatments for PPH. 
As soon as primary PPH is diagnosed, the study drug (TXA or pla-
cebo) will be administered as soon as possible alongside all other 
clinically indicated treatments for PPH. Each trial treatment pack 
contains two doses, and each dose contains two ampoules of 500mg 
TXA or placebo (sodium chloride 0.9%).
Outcomes
Measures of the primary and secondary outcomes of ETAPlaT 
study. The primary outcome will be the effect of TXA on thrombin 
generation [thrombin generation assay (TGA) parameter – endog-
enous thrombin potential (ETP)]. Secondary outcomes will include 
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the effect of TXA on platelet function (Multiplate® tests: ADPtest 
and TRAPtest), fibrinogen, D-dimer and FV, FVIII, vWF levels, 
and other TGA parameters [lag time (LT); time to peak (TtP); and 
peak height (Ph)]. Levels of all parameters will be assessed on two 
venous blood samples, collected at the baseline and between 30±15 
minutes after the first dose of study treatment is given.
Further secondary outcomes will include assessment of the relation-
ship between these parameters, patient demographics and clinical 
data (in the time frame from randomization to the patient discharge 
from the hospital or until 42 days).
Outcomes of the main study WOMAN trial. The WOMAN trial 
will not provide information about platelet function, thrombin gen-
eration, fibrinogen, D-dimers and coagulation factors V, VIII and 
vWF in patients receiving TXA/placebo. However, the most reli-
able estimates of the effects of TXA on the outcomes for women 
with PPH will be provided by the WOMAN trial.
Sample size
We aim to assess if TXA, when compared to a placebo, has an 
effect on change over time on the TGA parameter, ETP. Therefore, 
the sample size calculation is based on this parameter. Patients 
are expected to be equally allocated between the two intervention 
groups; 88 patients per group (total, 176 patients) are needed to 
detect the difference of ETP 243nM/min, with a change between 
the groups at a 5% significance level with a power of 80%.
Randomization and blinding
Patients with a clinical diagnosis of PPH, who are eligible for the 
WOMAN trial, after having completed the informed consent proce-
dures, will be randomly assigned to receive either TXA or placebo. 
Patients randomised in the trial will receive the study drug (TXA/
placebo) by intravenous injection. The lowest available number of 
the pack will be used first and then subsequently other packs from 
the box that contains 8 study treatment packs. The blinding process 
will be carried out by an independent supplier, who will mark the 
study drug with the blinded label. The vials and packages will be 
the same, and the randomisation number will be used as the pack 
identification.
Procedures before/after the study treatment administration, 
blood sample collection and analysis
Immediately after patient is randomized, two test tubes (3mL and 
5mL) of venous blood will be taken and the first dose of trial treat-
ment will be administered. About 30±15 minutes after the admin-
istration of the first dose of trial drugs, two more test tubes (3mL 
and 5mL) of venous blood will be collected. If a woman continues 
to bleed and a second dose of trial treatment is required, the second 
blood sample will be taken before this is given (Figure 1).
Figure 1. Algorithm of the WOMAN-ETAPlaTsub-study. Black boxes: Standard procedure of the WOMAN trial. Red boxes: Additional 
procedures required for the ETAPlaT sub-study.
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Samples of the 3mL tubes (hirudine) whole blood will be analyzed 
immediately at the hospital in Tirana, Albania for platelet function 
using a Multiplate Platelet Function Analyzer (Dynabyte GmbH, 
Munich, Germany).
Samples of 5mL tubes (sodium citrate 3.2%) will be centrifuged 
immediately at 3000xg for 20 minutes, and platelet poor plasma 
samples will be divided ito two aliquots and preserved at -80°C. 
These will be transferred to dry ice for later analysis at the Insti-
tute of Laboratory Medicine, German Heart Centre in Munich, 
Germany for TGA, fibrinogen, D-dimers, and FV, FVIII and vWF 
levels. The temperature storage conditions of the plasma samples 
will be monitored and recorded daily.
As part of the routine protocol of the hospital, a blood sample for 
complete blood count (CBC) is taken from every woman in labour 
prior to delivery. In cases of PPH randomized in the study, another 
CBC is performed after 4 hours and within 12 hours, depending 
on the severity of PPH. The pre-post randomization difference in 
CBC parameters, such as haemoglobin or haematocrit drop, will 
be evaluated.
Standard operating procedures for handling, storage and analysis 
of the blood samples and the process for transferring the data to the 
Trial Coordinating Centre (TCC) are developed by each responsible 
Institution, and are approved by TCC. Copies are available from the 
Trial Master File.
Ethical considerations, recruitment and consent
Ethical approval for WOMAN ETAPlaT protocols was obtained 
28.10.2013 (ref. 6518) from the London School of Hygiene and 
Tropical Medicine (LSHTM) Ethics Committee in London, United 
Kingdom, and by the National Ethics Committee in Tirana, Alba-
nia on 11.07.2013 (ref. 62) and amendment on 01.12.2014 (ref. 
81). PPH is an obstetric emergency and it is not possible to predict 
which women that will have this complication. In this emergency 
situation it is important to carry out an informed consent procedure, 
according to regulatory requirements, and adhere to the ICH-GCP 
and Declaration of Helsinki, for patients to be eligible for the study. 
The consent procedure will be performed as per the approved pro-
cedure for the WOMAN trial.
Briefly, advanced information about the trial will be given to 
pregnant women, which will make the recruitment and consent 
procedure easier. The consent process will depend on the clini-
cal emergency and the patient’s physical or emotional state. If the 
woman is fully competent, the healthcare giver will provide infor-
mation and discuss with her about the study and obtain informed 
written consent (Supplementary File 1 and Supplementary 
File 2). If the woman’s mental or physical capacity does not allow 
her to give consent, the woman’s relative or representative, if 
available, should be informed about the trial and informed writ-
ten consent will be obtained by them (Supplementary File 1 and 
Supplementary File 3). Where no relatives or representative are 
available, a waiver of prior written consent has been approved for 
the WOMAN trial. Where a waiver of prior written consent is used, 
the woman, relative or representative should be asked for consent 
for the continuation of the trial procedure.
To minimize the need for multiple information sheets and con-
sent forms, one form, which combines the WOMAN trial and the 
WOMAN-ETAPlaT study, will be used.
Data collection and monitoring
Data collection
All study data will be gathered on the WOMAN trial entry data 
form (baseline information) and outcome data form (patient death, 
discharge from the hospital or 42 days after randomization). Addi-
tional information will be collected with ETAPlaT data collection 
forms (Supplementary File 4). All study data will be sent electroni-
cally to the main database of the TCC in London, UK. ETAPlaT 
data collection forms will include the following:
•  Time when the blood sample was taken and laboratory 
analysis was started and completed, and any technical prob-
lems with analysis;
•  Laboratory results of Multiplate analysis (ADPtest, TRAPtest), 
TGA, D-dimer, fibrinogen, F V, FVIII and vWF;
•  Treatment given that may affect coagulation;
•  Other data about the woman’s parity, BMI, gestational age at 
birth, maternal pre-existing conditions (anaemia, cardiac dis-
ease, haemoglobinopathy, chronic hypertension, renal disease, 
treatment or prophylaxis with antithrombotic drugs, or history 
of previous thromboembolism), pregnancy related conditions 
(preeclampsia, diabetes, infection, placental abruption), labour 
induction/augmentation and duration, anaesthesia (epidural, 
spinal or general), birth weight, additional doses of uteroton-
ics (oxytocin/methergine).
Analysis
Analysis will compare two groups of randomized patients, allo-
cated in TXA group or placebo group on an intention-to-treat basis, 
regardless of treatment received, and outcomes will be presented as 
appropriate effect estimates and 95% confidence intervals.
In analysis of primary outcome, TXA and placebo groups will 
be compared regarding the TGA parameter, ETP of baseline 
and follow up values. The same analysis will be performed for 
secondary outcomes such as platelet function (ADPtest and 
TRAPtest), coagulation factors (FV; FVIII; vWF, Fibrinogen and 
D-Dimer) and other TGA parameters (LT, TtP, and Ph). A sub-
group analysis for primary outcome will be based on main risk 
factors for PPH, such as uterine atony, placental factors and genital 
trauma.
A detailed statistical analysis plan (SAP) will be finalized prior to 
the sub-study unblinding for final analysis. All statistical analysis 
will be conducted with R and STATA statistical package.
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Limitations of the study
One limitation of this sub-study is the small number of the patients 
that will be recruited. Another potential limitation is withdrawal of 
participation by patients from this study, or risk of loss of contact in 
case of complications after discharge from the hospital and within 
the period of 42 days after the birth.
Trial Steering Committee (TSC) and Data Monitoring 
Committee (DSC)
A TSC for the WOMAN trial is in place and agreed to the conduct 
of this sub-study. Decisions of the TSC can influence immediately 
on the continuation of the WOMAN-ETAPlaT study. Information 
about the WOMAN-ETAPlaT study will be reported routinely to 
the TSC by Haleema Shakur. An independent DMC is already in 
place for the WOMAN trial. Adverse events, which occur during 
the study period and are related directly to the WOMAN-ETAPlaT 
study, will be reported to the DMC.
The sub-study had its responsibilities coordinated by the TCC, 
which may attribute responsibilities to third parties, and will be 
detailed by suitable arrangements.
Trial status
Recruitment for the WOMAN ETAPlaT sub-study started on 
November 2013 and the final participant follow-up was completed 
in March 2015. Data cleaning is ongoing.
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 Loïc Sentilhes
Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France
The authors have published their protocol of a WOMAN trial sub-study.
WOMAN is a pragmatic, randomized, double-blinded, placebo-controlled trial in women with a clinical
diagnosis of postpartum hemorrhage (PPH) and is intended to determine reliably the effect of the early
administration of TXA on death, hysterectomy, and other morbidity (surgical intervention, blood
transfusion and risk of nonfatal vascular events). Recruitment of the 20,000 planned randomized women
has been completed as well as statistical analysis.
The aim of this sub-study is to assess the effect of TXA on thrombin generation but also on platelet
function, fibrinogen, D-dimer and coagulation factors in women with PPH. The authors hypothesize that
TXA will decrease thrombin generation by inhibiting plasmin and modify platelet activity, coagulation
factors V and VIII and Von Willebrand levels in women with PPH. The protocol of the WOMAN trial has
been previously published elsewhere.
In this sub-study, it is planned, only on a single site located in Albania, to obtain blood samples
immediately after randomization and before the administration of the first dose of trial treatment as well as
about 30±15 minutes after the administration of the first dose of trial drugs (but before the second dose of
trial treatment if required).
Platelet function will be assessed immediately on site using Multiplate®tests, while other samples will be
centrifugated and preserved at -80°C to be transferred in Germany for later analysis of Thrombin
generation Assay, fibrinogen, D-dimers, coagulation factors V and VIII and Von Willebrand levels.
The protocol is well written, original and will provide useful, interesting and likely robust data related to the
impact of TXA on hemostasis of PPH women. I have only minor comments.
The authors should explain why only one site participates to the WOMAN trial sub-study.
 
The primary outcome should be clinically (and in pathophysiological manner) justified:
Endogenous Thrombin Potential difference of 243nM/min.  
 
The sample size should be based on literature or the authors should mention that, as this analysis
is exploratory, it is somewhat arbitrary.
 
The authors should clearly note that analysis will be performed blindly.
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The authors should clearly note that analysis will be performed blindly.
 
The authors should clearly mention what material laboratory will be used to assess Thrombin
generation Assay, fibrinogen, D-dimers, coagulation factors V and VIII and Von Willebrand levels.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 I am the main investigator of the TRAAP (TRAnexamic Acid for PreventingCompeting Interests:
postpartum hemorrhage after vaginal delivery) study: a multicenter randomized, double-blind,
placebo-controlled trial which aims to determine whether a low dose of TXA (1 g) after vaginal delivery
reduces the incidence of postpartum hemorrhage (Sentilhes L, Daniel V, Darsonval A, Deruelle P, Vardon
D, Perrotin F, Le Ray C, Senat MV, Winer N, Maillard F, Deneux-Tharaux C. Study protocol. TRAAP -
TRAnexamic Acid for Preventing postpartum hemorrhage after vaginal delivery: a multicenter
randomized, double-blind, placebo-controlled trial. BMC Pregnancy Childbirth. 2015 Jun 14;15:135. doi:
10.1186/s12884-015-0573-5.).
 03 January 2017Referee Report
doi:10.21956/wellcomeopenres.10739.r18827
,  Anne-Sophie Ducloy-Bouthors Emmanuelle Jeanpierre
 Pôle d'Anesthésie-Réanimation, Hôpital Jeanne-de-Flandre, CHRU Lille, Lille, France
 Department of Hematology and Transfusion, Centre de Biology Pathology, Centre Hospitalier Régional,
Lille, France
The authors plan to conduct a sub-study within the WOMAN trial. Among the women experiencing
clinically diagnosed primary PPH after vaginal or caesarean delivery and included in the WOMAN trial,
blood samples will be collected at baseline and 30 minutes after the first dose of study treatment. Using
platelet poor plasma, thrombin generation, fibrinogen, D-dimer, factor V and VIII, and Von Willebrand
factor will be measured. Platelet function will be evaluated in whole blood using Multiplate® tests. The
primary outcome is the effect of TXA on thrombin generation. Secondary outcomes include the effect of
TXA on platelet function, fibrinogen, D-dimer and coagulation factors.
The title is appropriate for the content of the article and the abstract represent a suitable summary of the
work. The trial is well described regarding the background, the method and the expected results. The
conclusions are sensible, balanced and justified on the basis of the results of the study.This paper is of
interest to explore the hypothesis of TA-related thrombin generation inhibition and I recommend indexing
it with minor corrections.
One suggestion and the aim of our TRACES trial [CT 02797119] should be to analyze
simultaneously the plasmin inhibition to link the force of the thrombin procoagulant effect and
plasmin TA inhibition.
 
Please clarify which laboratory will perform the biological tests and the expected delay between the
samples and the LAB analysis.
 
Please clarify if the biological data analysis will be blinded to the allocation?
1 2
1
2
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Please clarify if the biological data analysis will be blinded to the allocation?
 
I believe the data is in a usable format/structure and there is sufficient information provided for the
experiment to be replicated.
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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